All News

Data from the phase 3 ZIRCON trial evaluating 89Zr-DFO-girentuximab in patients with renal tumors may be practice changing, according to an expert from the University of California Los Angeles.

Investigators will assess INB-400 as a treatment for patients with newly diagnosed glioblastoma in a phase 2 trial expected to initiate in the second half of 2023.

Rakhshanda Rahman, MD, FRCS, FACS, emphasizes the importance of educating patients and physicians on the potential risks and benefits of new approaches and technologies involved in the de-escalation of breast cancer treatment.

Treatment with isolated hepatic perfusion appears to yield improved progression-free survival compared with best alternative care in patients with isolated uveal melanoma liver metastases.

An ancillary analysis of 2 clinical trials finds that pathologic complete response may be a prognostic factor of clinical outcomes in soft tissue sarcoma in future studies.

A recovery tracker and other digital tools may be useful in helping to manage patient symptoms following debulking surgery for gynecologic cancer, according to an expert from Memorial Sloan Kettering Cancer Center.

The addition of pembrolizumab to conventional chemotherapy appears tolerable and effective in a cohort of patients with relapsed/refractory classic Hodgkin lymphoma, according to data from a phase 2 trial.

According to an expert from University Hospitals, integrative oncology has a place in the treatment of patients with kidney cancer alongside palliative care, psycho-oncology, and physical therapy.

Investigators say that among those with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma who responded to nivolumab plus ipilimumab duration of response was not reached.

An artificial intelligence-based model for detecting lymph node metastases appears to identify tumor micrometastases in bladder cancer that pathologists may miss while classifying patient results as negative.

Combination treatment with IMX-110 and tislelizumab yields no dose-limiting toxicities thus far in the first cohort of patients with advanced/metastatic colorectal cancer in the phase 1b/2a IMMINENT-01 trial.

Common symptoms following debulking surgery for gynecologic cancer appear to include pain, diarrhea, and nausea, according to an expert from Memorial Sloan Kettering Cancer Center.

Pharmacy director Kirollos Hanna, PharmD, BCPS, BCOP, FACC, discusses how to navigate shared toxicities between combination immunotherapy and VEGF inhibitors for patients with renal cell carcinoma.

The FDA’s approval of the FoundationOne Liquid CDx assay may improve access to treatment with mobocertinib for patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.

Based on findings from the phase 3 MIRASOL trial, investigators plan to submit a supplemental biologics license application for mirvetuximab soravtansine in folate receptor α–positive platinum-resistant ovarian cancer.

According to an expert from University Hospitals, oncologists should work together and look for opportunities to improve patients’ diets and exercise routines to mitigate symptoms of kidney cancer and associated treatment.

According to the investigators of the INSITE trial, the potential benefit of pegulicianine fluorescence–guided surgery in breast cancer warrants investigation in future studies.

ERAS-801, which now has FDA fast track designation for glioblastoma with EGFR alterations, is currently under investigation as a monotherapy in the phase 1 THUNDERBBOLT-1 trial.

Patients in Canada who have advanced non–small cell lung cancer can now receive cemiplimab plus chemotherapy as a first-line treatment following Health Canada’s approval of the regimen.

THIO plus cemiplimab does not appear to yield any dose-limiting toxicities or significant treatment-related adverse effects in patients with advanced non–small cell lung cancer.

Enzalutamide with or without leuprolide also reduces the risk of prostate-specific antigen progression in those with non-metastatic hormone-sensitive prostate cancer in the phase 3 EMBARK trial.

Liso-cel produces no new safety signals in relapsed or refractory mantle cell lymphoma and follicular lymphoma in the phase 1 TRANSCEND NHL 001 trial and the phase 2 TRANSCEND FL trial.

Data from the phase 3 COMMANDS trial support a supplemental biologics license application for an expanded indication for luspatercept-aamt for lower-risk myelodysplastic syndrome with anemia.

During the ODAC meeting, members voted to restrict the use of olaparib plus abiraterone and prednisone or prednisolone to patients with BRCA-mutated metastatic castration-resistant prostate cancer.

xT CDx is a 648-gene next-generation sequencing panel capable of determining microsatellite instability status in patients with colorectal cancer.

Javier Orozco-Mera, MD, FACS, MSc, discusses signaling pathways and molecular mechanisms involved in the relapse of glioblastoma.

According to an expert from University Hospitals, studying pathways related to inflammation, epigenetics, and the microbiome may elucidate how patients with kidney cancer respond to anti-cancer therapy.

The addition of short-term androgen deprivation to dose-escalated radiation therapy did not yield a significant difference in quality-of-life outcomes vs radiotherapy alone for those with intermediate-risk prostate cancer, according to an expert from Henry Ford Health Cancer.

The novel radiotherapy Iomab-B prolongs survival and improves clinical outcomes among patients with relapsed/refractory acute myeloid leukemia, according to data from the phase 3 SIERRA trial.

James J. Driscoll, MD, PhD, and James Ignatz-Hoover, MD, PhD, share a perspective on a study published recently in ONCOLOGY.